Redux Lawsuits

On September 15, 1997, the FDA announced that they were withdrawing dexfenfluramine and fenfluramine, marketed under the name Redux and Pondimin. This action was based on post marketing reports from the Mayo Clinic of 24 cases of heart valve disease in some patients that were treated with the combination of phentermine and fenfluramine. Boxed warnings were added to Redux and Pondimin labeling on July 25, 1997, prior to the recall to warn of the concern for possible heart valve disease.

More adverse Redux heart valve findings were also found to occur. Cases of heart disease and heart damage have continued to surface because of the delayed diagnoses that can often result because of the non-evident symptoms. The once popular Redux diet drug has resulted in a Nationwide Class Action Settlement Agreement that received Final Judicial Approval on January 3, 2002.

Redux has been directly linked to instances of primary pulmonary hypertension, as well as other adverse side effects. When using Redux for three months or longer is associated with a twenty-three fold increase in risk of developing primary pulmonary hypertension. Redux manufacturer failed to properly warn patients that the deadly condition of PPH could occur. People are still experiencing the serious adverse effects of Redux due to the latency period that PPH and other side effects can have. If you have taken Redux and would like to learn more about your rights, please contact us.

Links 1 2